Cargando…

DCLK1 immunoreactivity in colorectal neoplasia

INTRODUCTION: Microtubule-associated doublecortin and CaM kinase-like-1 (DCLK1) is a novel candidate marker for intestinal stem cells. The aim of our study was to assess DCLK1 immunoreactivity in colorectal carcinogenesis and its correlation with prognosis. METHODS: DCLK1 immunostaining was performe...

Descripción completa

Detalles Bibliográficos
Autores principales: Gagliardi, Giuseppe, Goswami, Monica, Passera, Roberto, Bellows, Charles F
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3340108/
https://www.ncbi.nlm.nih.gov/pubmed/22557932
http://dx.doi.org/10.2147/CEG.S30281
_version_ 1782231433158328320
author Gagliardi, Giuseppe
Goswami, Monica
Passera, Roberto
Bellows, Charles F
author_facet Gagliardi, Giuseppe
Goswami, Monica
Passera, Roberto
Bellows, Charles F
author_sort Gagliardi, Giuseppe
collection PubMed
description INTRODUCTION: Microtubule-associated doublecortin and CaM kinase-like-1 (DCLK1) is a novel candidate marker for intestinal stem cells. The aim of our study was to assess DCLK1 immunoreactivity in colorectal carcinogenesis and its correlation with prognosis. METHODS: DCLK1 immunostaining was performed in colorectal tissue from 71 patients, including 18 adenomatous polyps, 40 primary adenocarcinomas, and 14 metastatic lesions. Each case was evaluated by a combined scoring method based on the intensity of staining (score 0–3) and the percentage of tissue staining positive (score 0–3). Immunoexpression for DCLK1 was considered as positive when the combined score was 2–6 and negative with a score of 0–1. RESULTS: Overall, 14/18 (78%) of polyps, 30/40 (75%) of primary adenocarcinomas, and 7/14 (50%) of distant metastases were positive for DCLK1. In adenomatous polyps and primary cancer there was no association between DCLK1 staining score and tumor pathology. However, after curative colorectal cancer resection, patients whose tumor had a high (≥5) combined staining score had increased cancer-specific mortality compared to patients with low (0–4) staining score (hazard ratio 5.89; 95% confidence interval: 1.22–28.47; P = 0.027). CONCLUSION: We found that DCLK1 is frequently expressed in colorectal neoplasia and may be associated with poor prognosis. Further studies are necessary to validate the use of DCLK1 as a prognostic marker.
format Online
Article
Text
id pubmed-3340108
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-33401082012-05-03 DCLK1 immunoreactivity in colorectal neoplasia Gagliardi, Giuseppe Goswami, Monica Passera, Roberto Bellows, Charles F Clin Exp Gastroenterol Original Research INTRODUCTION: Microtubule-associated doublecortin and CaM kinase-like-1 (DCLK1) is a novel candidate marker for intestinal stem cells. The aim of our study was to assess DCLK1 immunoreactivity in colorectal carcinogenesis and its correlation with prognosis. METHODS: DCLK1 immunostaining was performed in colorectal tissue from 71 patients, including 18 adenomatous polyps, 40 primary adenocarcinomas, and 14 metastatic lesions. Each case was evaluated by a combined scoring method based on the intensity of staining (score 0–3) and the percentage of tissue staining positive (score 0–3). Immunoexpression for DCLK1 was considered as positive when the combined score was 2–6 and negative with a score of 0–1. RESULTS: Overall, 14/18 (78%) of polyps, 30/40 (75%) of primary adenocarcinomas, and 7/14 (50%) of distant metastases were positive for DCLK1. In adenomatous polyps and primary cancer there was no association between DCLK1 staining score and tumor pathology. However, after curative colorectal cancer resection, patients whose tumor had a high (≥5) combined staining score had increased cancer-specific mortality compared to patients with low (0–4) staining score (hazard ratio 5.89; 95% confidence interval: 1.22–28.47; P = 0.027). CONCLUSION: We found that DCLK1 is frequently expressed in colorectal neoplasia and may be associated with poor prognosis. Further studies are necessary to validate the use of DCLK1 as a prognostic marker. Dove Medical Press 2012-04-11 /pmc/articles/PMC3340108/ /pubmed/22557932 http://dx.doi.org/10.2147/CEG.S30281 Text en © 2012 Gagliardi et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Original Research
Gagliardi, Giuseppe
Goswami, Monica
Passera, Roberto
Bellows, Charles F
DCLK1 immunoreactivity in colorectal neoplasia
title DCLK1 immunoreactivity in colorectal neoplasia
title_full DCLK1 immunoreactivity in colorectal neoplasia
title_fullStr DCLK1 immunoreactivity in colorectal neoplasia
title_full_unstemmed DCLK1 immunoreactivity in colorectal neoplasia
title_short DCLK1 immunoreactivity in colorectal neoplasia
title_sort dclk1 immunoreactivity in colorectal neoplasia
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3340108/
https://www.ncbi.nlm.nih.gov/pubmed/22557932
http://dx.doi.org/10.2147/CEG.S30281
work_keys_str_mv AT gagliardigiuseppe dclk1immunoreactivityincolorectalneoplasia
AT goswamimonica dclk1immunoreactivityincolorectalneoplasia
AT passeraroberto dclk1immunoreactivityincolorectalneoplasia
AT bellowscharlesf dclk1immunoreactivityincolorectalneoplasia